Agere Augments Leadership with Pharmaceutical Manufacturing and Supply Chain Expert
News May 30, 2013
Agere Pharmaceuticals, Inc. announced today that Mr. Michael R. Deperro has joined the company as VP of Operations. The company added cGMP manufacturing capabilities in 2011, and since has expanded facilities to produce Phase I through Phase IIb clinical trials materials for clients.
“Mike brings Agere extensive experience and a strong track record for successfully managing and growing cGMP operations,” commented Marshall Crew, President and CEO of Agere. “He will play a key role as we continue our rapid growth to meet the rigorous expectations of our clients.”
Mr. Deperro has held director and GM-level manufacturing positions at numerous pharmaceutical companies including Alkermes and Taro Pharmaceuticals. He has also been responsible for implementing research and manufacturing infrastructure and operations domestically and abroad for large pharmaceutical and biotechnology companies including Merck and Co. and Novartis. Mr. Deperro’s career focus has been in the areas of drug development, new product launch, and commercialization. His regulatory compliance knowledge of FDA, MHRA, PMDA and ANVISA agencies enhances Agere’s strength in meeting the needs of a growing international client base. Mr. Deperro holds the Bachelor of Science degree in Mechanical Engineering from Notre Dame University, and has earned the Six Sigma Yellow Belt status from the International Society for Six Sigma Certifications.
A new study reveals that preventive medications – such as those to lower blood pressure or cholesterol, or to protect bone health, among others – are commonly prescribed during the last year of life of older adults with cancer, even though they are unlikely to provide meaningful benefits.READ MORE